<DOC>
	<DOCNO>NCT00229775</DOCNO>
	<brief_summary>The purpose study determine whether artemether + lumefantrine effective chloroquine + sulfadoxine pyrimethamine treatment uncomplicated Plasmodium falciparum malaria</brief_summary>
	<brief_title>Efficacy Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine Treatment Uncomplicated Plasmodium Falciparum Malaria Philippines</brief_title>
	<detailed_description>Background : In Philippines , close 11 million people 65 province risk acquire malaria infection . It still one ten lead cause morbidity nationwide . Each day , roughly 150-200 people fall ill malaria . In past 40 year , mortality rate stabilize around 2/100,000 population . Of people malaria , approximately 1 % die per year . Malaria remain one major cause death province Palawan , Isabela , Tawi-tawi , Sulu Butuan City . Approximately 70 % malaria Philippines Plasmodium falciparum remain specie P. vivax . Recently Department Health ( DOH ) institute change national antimalarial drug guideline change use chloroquine ( CQ ) sulfadoxine pyrimethamine ( SP ) monotherapy first second line drug , respectively , combine chloroquine plus sulfadoxine-pyrimethamine first-line treatment , artemether-lumefantrine ( Coartem ) second line treatment . This change make due increasing level drug resistance previous first second-line therapy . In order improve understanding trend antimalarial drug resistance Philippines , DOH initiate sentinel surveillance system monitor antimalarial drug resistance . Three site select representative country . Objective : To establish sentinel surveillance system assess efficacy chloroquine plus sulfadoxine-pyrimethamine versus artemether + lumefantrine treatment uncomplicated P. falciparum infection three area Republic Philippines . Methods : An vivo antimalarial drug efficacy trial conduct three area Philippines . Subjects &gt; 6 month age parasitologically confirm , uncomplicated P. falciparum infection recruit . Patients treat single dose SP ( 25 mg/kg sulfadoxine component single dose ) plus CQ ( 25 mg/kg three day ) artemether + lumefantrine ( twice daily ) 3 day . Patients randomly assign one two drug regimen . Clinical parasitological parameter monitor 28-day follow-up period evaluate drug efficacy . Results study use assist DOH assess national malaria treatment policy P. falciparum malaria .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<criteria>1 . Weight &gt; 10 kg ; 2 . Documented fever ( axillary temperature &gt; 37.5oC ) and/or history fever previous 24 hour absence another obvious cause fever ( pneumonia , measles , otitis medium ) ; 3 . Monoinfection P. falciparum 1,000 100,000 asexual parasites/µl determine microscopic examination thick , thick thin peripheral blood smear ; 4 . Informed consent patient parent/guardian ( case child ) , assent child ( age 8 17 year inclusive ) ; 5 . Willingness part patient return clinic regular checkup 28day followup period . 1 . Danger sign : unable drink breastfeed ; vomit ( twice previous 24 hour ) ; recent history convulsion ( one previous 24 hour ) ; impaired consciousness ; unable sit stand ; 2 . Severe Manifestations P. falciparum malaria adult child ( World Health Organization criterion ) 1 . Prostration ( inability sit unassisted [ child ] , extreme weakness [ adult ] ) 2 . Impaired consciousness ( Blantyre coma scale [ child ] , Glascow coma scale [ adult ] ) 3 . Respiratory distress ( sustain nasal flare , indrawing , Kussmaul breathe ) 4 . Multiple convulsion ( ³2 convulsions/24 hour period ) 5 . Circulatory collapse ( hypotension poor perfusion ) 6 . Pulmonary edema 7 . Abnormal bleed 8 . Jaundice 9 . Hemoglobinuria 10 . Severe anemia ( Hb &lt; 5 gm/dL ) 11 . Hypoglycemia ( blood glucose &lt; 2.2 mmol/L [ &lt; 40 mg/dL ] ) 12 . Acidosis ( bicarbonate &lt; 15 mmol/L ) 13 . Hyperparisitemia ( level varies endemicity ) 14 . Renal impairment ( urine output &lt; 12 mL/kg/24 hour ) 3 . Other underlie chronic severe disease ( e.g. , cardiac , renal , hepatic disease , HIV/AIDS , malnutrition ) ; 4 . History hypersensitivity reaction drug test used alternative treatment : sulfonamide , chloroquine , artemisinins , artemether , lumefantrine , quinine tetracycline/clindamycin ; 4 . Pregnancy ( history pregnancy positive urine pregnancy test ) ; 5 . Women breast feed child less 8 week age .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Plasmodium falciparum malaria</keyword>
	<keyword>malaria</keyword>
	<keyword>artemether lumafantrine</keyword>
	<keyword>chloroquine</keyword>
	<keyword>sulfadoxine pyrimethamine</keyword>
	<keyword>Coartem</keyword>
</DOC>